JP2014502253A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014502253A5 JP2014502253A5 JP2013532271A JP2013532271A JP2014502253A5 JP 2014502253 A5 JP2014502253 A5 JP 2014502253A5 JP 2013532271 A JP2013532271 A JP 2013532271A JP 2013532271 A JP2013532271 A JP 2013532271A JP 2014502253 A5 JP2014502253 A5 JP 2014502253A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- antibody
- acid sequence
- sequence
- difficile
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000193163 Clostridioides difficile Species 0.000 claims 42
- 125000003275 alpha amino acid group Chemical group 0.000 claims 38
- 108020001507 fusion proteins Proteins 0.000 claims 25
- 102000037865 fusion proteins Human genes 0.000 claims 25
- 101710182223 Toxin B Proteins 0.000 claims 19
- 101710084578 Short neurotoxin 1 Proteins 0.000 claims 18
- 101710182532 Toxin a Proteins 0.000 claims 18
- 241000894006 Bacteria Species 0.000 claims 6
- 206010011409 Cross infection Diseases 0.000 claims 6
- 239000000427 antigen Substances 0.000 claims 6
- 108091007433 antigens Proteins 0.000 claims 6
- 102000036639 antigens Human genes 0.000 claims 6
- 208000015181 infectious disease Diseases 0.000 claims 6
- 125000000539 amino acid group Chemical group 0.000 claims 4
- 239000003242 anti bacterial agent Substances 0.000 claims 4
- 229940088710 antibiotic agent Drugs 0.000 claims 4
- 238000000338 in vitro Methods 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 239000000523 sample Substances 0.000 claims 4
- 239000003053 toxin Substances 0.000 claims 3
- 231100000765 toxin Toxicity 0.000 claims 3
- 108700012359 toxins Proteins 0.000 claims 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims 2
- 206010029803 Nosocomial infection Diseases 0.000 claims 2
- 230000002238 attenuated effect Effects 0.000 claims 2
- 238000002648 combination therapy Methods 0.000 claims 2
- 238000003018 immunoassay Methods 0.000 claims 2
- 239000013610 patient sample Substances 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 230000001629 suppression Effects 0.000 claims 2
- 102000005927 Cysteine Proteases Human genes 0.000 claims 1
- 108010005843 Cysteine Proteases Proteins 0.000 claims 1
- 241000282412 Homo Species 0.000 claims 1
- 235000001014 amino acid Nutrition 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 238000012790 confirmation Methods 0.000 claims 1
- 239000012636 effector Substances 0.000 claims 1
- 108091006058 immobilized fusion proteins Proteins 0.000 claims 1
- 230000003100 immobilizing effect Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000011159 matrix material Substances 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 238000005406 washing Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1016742.7A GB201016742D0 (en) | 2010-10-05 | 2010-10-05 | Clostridium difficile antigens |
| GB1016742.7 | 2010-10-05 | ||
| PCT/GB2011/051910 WO2012046061A2 (en) | 2010-10-05 | 2011-10-05 | Clostridium difficile antigens |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014502253A JP2014502253A (ja) | 2014-01-30 |
| JP2014502253A5 true JP2014502253A5 (cg-RX-API-DMAC7.html) | 2014-11-13 |
| JP6377907B2 JP6377907B2 (ja) | 2018-08-22 |
Family
ID=43243528
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013532271A Active JP6377907B2 (ja) | 2010-10-05 | 2011-10-05 | クロストリジウム・ディフィシル（Ｃｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅ）抗原 |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US10369206B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2625193B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6377907B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN103237807B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2011311321B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112013008407A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2812731C (cg-RX-API-DMAC7.html) |
| GB (1) | GB201016742D0 (cg-RX-API-DMAC7.html) |
| SG (1) | SG189058A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2012046061A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201016742D0 (en) | 2010-10-05 | 2010-11-17 | Health Prot Agency | Clostridium difficile antigens |
| BR112013027229B1 (pt) | 2011-04-22 | 2020-10-27 | Wyeth Llc | polipeptídeo imunogênico isolado e seu uso, composição imunogênica e seu uso, célula recombinante ou progênie da mesma, e método de produção de uma toxina de clostridium difficile mutante |
| DK2714910T3 (en) * | 2011-05-27 | 2018-02-05 | Glaxosmithkline Biologicals Sa | Immunogenic composition |
| BR112014013876A2 (pt) * | 2011-12-08 | 2019-09-24 | Novartis Ag | vacina à base de toxina de clostridium difficile |
| GB201206070D0 (en) * | 2012-04-04 | 2012-05-16 | Health Prot Agency | Clostridium difficile antigens |
| BR122016023101B1 (pt) | 2012-10-21 | 2022-03-22 | Pfizer Inc | Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile |
| AU2013352034B2 (en) * | 2012-11-28 | 2018-08-02 | Emergent Biosolutions Canada Inc. | Antibodies against Clostridium difficile |
| CN103865938B (zh) * | 2012-12-16 | 2016-10-05 | 山东国际生物科技园发展有限公司 | 艰难梭菌外毒素a羧基端序列密码子优化基因片段、表达载体构建方法及其表达蛋白的应用 |
| US9493518B2 (en) * | 2013-03-14 | 2016-11-15 | National Health Research Institutes | Compositions and methods for treating clostridium difficile-associated diseases |
| EP2988778A4 (en) * | 2013-04-22 | 2016-12-14 | Board Of Regents Of The Univ Of Oklahoma | CLOSTRIDIUM DIFFICILE IMPREGENT AND METHOD OF USE |
| GB201309421D0 (en) * | 2013-05-24 | 2013-07-10 | Imp Innovations Ltd | Polypeptides |
| CN103772509B (zh) * | 2014-01-20 | 2017-01-11 | 山东国际生物科技园发展有限公司 | 一种艰难梭菌毒素a/b的融合蛋白及其编码基因与应用 |
| EP3344276B1 (en) * | 2015-09-03 | 2020-04-22 | The Board of Regents of the University of Oklahoma | Peptide inhibitors of clostridium difficile tcdb toxin |
| US12252515B2 (en) * | 2018-01-16 | 2025-03-18 | Children's Medical Center Corporation | Compositions and methods for inhibiting Wnt signaling |
| US11136360B2 (en) * | 2018-12-19 | 2021-10-05 | Tsinghua University | Fusion proteins comprising a Mtu ΔI-CM intein variant and methods of protein purification |
| US11560235B2 (en) * | 2021-02-09 | 2023-01-24 | Joby Aero, Inc. | Aircraft propulsion unit |
| CN113717263B (zh) * | 2021-08-04 | 2022-06-07 | 河北医科大学第二医院 | 一种艰难梭菌特异性抗原肽 |
| CN115093470B (zh) * | 2022-06-30 | 2023-03-24 | 广州市乾相生物科技有限公司 | 内含肽Mtu RecA突变体及其在生产谷胱甘肽GSH中的应用 |
| CN120484111B (zh) * | 2025-05-14 | 2025-10-28 | 广州海绿生物技术有限公司 | 一种包含益生菌的组合物及其在治疗肠胃疾病中的用途 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| IL99552A0 (en) | 1990-09-28 | 1992-08-18 | Ixsys Inc | Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof |
| JP2002514886A (ja) * | 1994-10-24 | 2002-05-21 | プロメガ コーポレーション | クロストリジウム・ディフィシル疾患の治療及び予防のためのワクチン及び抗トキシン |
| US5919463A (en) | 1995-07-07 | 1999-07-06 | Oravax, Inc. | Clostridium difficle toxins as mucosal adjuvants |
| EP1000155A1 (en) | 1997-06-20 | 2000-05-17 | QUEEN MARY & WESTFIELD COLLEGE | Immunogenic fragments of toxin a of clostridium difficile |
| EP1169456B1 (en) | 1999-04-09 | 2012-07-11 | Intercell USA, Inc. | Recombinant production of Clostridium difficile Toxin A or Toxin B |
| AU2002232078A1 (en) | 2001-02-09 | 2002-08-19 | The Provost, Fellows And Scholars Of The College Of The Holy And Unidivided Trinity Of Queen Elizabe | Clostridium difficile vaccine |
| ES2533492T3 (es) * | 2004-02-06 | 2015-04-10 | University Of Massachusetts | Anticuerpos contra toxinas de Clostridium difficile y usos de los mismos |
| CN101500581B (zh) | 2006-06-08 | 2013-10-30 | 科内尔研究基金会 | 编码艰难梭菌毒素a和毒素b受体结合域的密码子优化dna分子及其使用方法 |
| US20120020996A1 (en) | 2008-08-06 | 2012-01-26 | Jonathan Lewis Telfer | Vaccines against clostridium difficile and methods of use |
| GB0921288D0 (en) | 2009-12-04 | 2010-01-20 | Health Prot Agency | Therapies for preventing or suppressing clostridium difficile infection |
| GB201016742D0 (en) | 2010-10-05 | 2010-11-17 | Health Prot Agency | Clostridium difficile antigens |
| BR112013027229B1 (pt) * | 2011-04-22 | 2020-10-27 | Wyeth Llc | polipeptídeo imunogênico isolado e seu uso, composição imunogênica e seu uso, célula recombinante ou progênie da mesma, e método de produção de uma toxina de clostridium difficile mutante |
-
2010
- 2010-10-05 GB GBGB1016742.7A patent/GB201016742D0/en not_active Ceased
-
2011
- 2011-10-05 CA CA2812731A patent/CA2812731C/en active Active
- 2011-10-05 EP EP11769913.2A patent/EP2625193B1/en active Active
- 2011-10-05 JP JP2013532271A patent/JP6377907B2/ja active Active
- 2011-10-05 AU AU2011311321A patent/AU2011311321B2/en active Active
- 2011-10-05 WO PCT/GB2011/051910 patent/WO2012046061A2/en not_active Ceased
- 2011-10-05 US US13/878,150 patent/US10369206B2/en active Active
- 2011-10-05 CN CN201180047913.3A patent/CN103237807B/zh active Active
- 2011-10-05 SG SG2013021506A patent/SG189058A1/en unknown
- 2011-10-05 BR BR112013008407A patent/BR112013008407A2/pt not_active IP Right Cessation
-
2019
- 2019-07-15 US US16/511,503 patent/US20190328859A1/en not_active Abandoned
-
2021
- 2021-04-07 US US17/224,404 patent/US20210369830A1/en active Pending
-
2022
- 2022-08-23 US US17/821,730 patent/US12491239B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014502253A5 (cg-RX-API-DMAC7.html) | ||
| Westritschnig et al. | A randomized, placebo-controlled phase I study assessing the safety and immunogenicity of a Pseudomonas aeruginosa hybrid outer membrane protein OprF/I vaccine (IC43) in healthy volunteers | |
| JP2012515551A5 (cg-RX-API-DMAC7.html) | ||
| JP2021038246A (ja) | 分泌様免疫グロブリンを含む組成物 | |
| PH12013500858A1 (en) | Binding proteins, including antibodies, antibody derivatives and antibody fragments that specifically bind cd 154 and uses thereof | |
| Pathirana et al. | Characterization of proteinase–adhesin complexes of Porphyromonas gingivalis | |
| JP2016519932A5 (cg-RX-API-DMAC7.html) | ||
| de Vor et al. | Human monoclonal antibodies against Staphylococcus aureus surface antigens recognize in vitro and in vivo biofilm | |
| JP6064241B2 (ja) | 黄色ブドウ球菌由来のα毒素に対するヒトモノクローナル抗体、及び膿瘍形成の治療又は予防におけるその使用 | |
| HRP20220918T1 (hr) | Anti-transtiretinska antitijela | |
| CN102365097A (zh) | 艰难梭菌毒素的抗体 | |
| JP2016504993A5 (cg-RX-API-DMAC7.html) | ||
| TW200626614A (en) | Human monoclonal antibodies to influenza M2 protein and methods of making and using same | |
| Botelho-Nevers et al. | Staphylococcal vaccine development: review of past failures and plea for a future evaluation of vaccine efficacy not only on staphylococcal infections but also on mucosal carriage | |
| JP2009536818A5 (cg-RX-API-DMAC7.html) | ||
| JP2007119468A (ja) | 通常のスタフィロコーカス抗原と反応する広い反応性のオプソニン抗体 | |
| RU2015106916A (ru) | Полипептиды clostridium difficile в виде вакцины | |
| JP2015529677A5 (cg-RX-API-DMAC7.html) | ||
| JP2008546648A (ja) | ブドウ球菌感染を治療および予防するためのＰａｎｔｏｎ−Ｖａｌｅｎｔｉｎｅロイコシジンの使用 | |
| JP2012523221A5 (cg-RX-API-DMAC7.html) | ||
| JP2013518563A5 (cg-RX-API-DMAC7.html) | ||
| JP2010529950A5 (cg-RX-API-DMAC7.html) | ||
| JP7643730B2 (ja) | ブドウ球菌（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ）プロテインＡ（ＳｐＡ）変種を含む方法および組成物 | |
| Makam et al. | Protective antigen and extractable antigen 1 based chimeric protein confers protection against Bacillus anthracis in mouse model | |
| Reglinski et al. | Treatment potential of pathogen-reactive antibodies sequentially purified from pooled human immunoglobulin |